Complex I Drives Glutamine-Dependent TCA Cycle to Support Viability of MYChigh Breast Cancer Cells
Anttila, J. M.; Savelius, M.; Somani, J.; Nicorici, D.; Munne, P. M.; Id, L.; Peura, A.; Hiltunen, A. O.; Aung, J.; Awadhpersad, R.; Prajapati, B.; Peltonen, M.; Ala-Hongisto, H.; Gautam, P.; Valimaki, M. J.; Tervonen, T. A.; Sapovalovaite, K.; Devarajan, R.; Perez, M. V. R.; Mutka, M.; Kovanen, P.; Niinikoski, L.; Meretoja, T.; Mattson, J.; Heikkila, P.; Wennerberg, K.; Arsenian-Henriksson, M.; Westermarck, J.; Aittokallio, T.; Goga, A.; Jackson, C. B.; Nieminen, A. I.; Klefstrom, J.
Show abstract
In many cancers, stably elevated MYC levels drive persistent and concerted activation of cell growth promoting anabolic programs and the cell cycle in ways that are distinct from normal cells. Therefore, synthetic-lethal strategies to target MYC reprograming of these pathways may identify new selective anticancer therapies for the treatment of MYChigh tumors. Here, we identify enhanced mitochondrial respiration as a hallmark of MYC overexpressing cancer cells. Mitochondrial respiration sustains the TCA cycle by regenerating NAD+ through complex I-mediated oxidation of NADH. Metabolic carbon tracing analysis revealed that MYC shifts TCA cycles carbon source from glucose to glutamine. Inhibition of the glutamine-fueled TCA cycle using NAD+-depleting complex I inhibitors resulted in MYC-dependent synthetic lethality in breast cancer cells. In mouse models of MYChigh tumors, persistent inhibition of tumor growth was achieved through combined inhibition of complex I and glutaminolysis. Our results suggest that the high respiration rate observed in MYChigh cells supports glutamine carbon-enriched TCA cycle, rendering MYChigh tumors selectively vulnerable to inhibitors of mitochondrial respiration and glutaminolysis.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer 98%
- CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells 98%
- C/EBPB-dependent Adaptation to Palmitic Acid Promotes Stemness in Hormone Receptor Negative Breast Cancer 97%
Similar papers in this journal
- RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination 96%
- GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton 96%
- Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer 96%
Similar papers in this journal
- Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer 96%
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 96%
- Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor 96%
Similar papers in this journal
- Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment 98%
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 96%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.